close

StemCells, Inc., a clinical-stage biotechnology company, focuses on the research, development, and commercialization of products derived from stem cell technologies. It focuses on developing cell-based therapeutics to treat diseases of the central nervous system and liver. The company's lead product candidate, HuCNS-SC cells are purified human neural stem cells, which can be expanded and banked until they are delivered as patient doses. StemCells has completed Phase I clinical trial of HuCNS-SC cells as a potential treatment for neuronal ceroid lipofuscinosis, a rare and fatal neurodegenerative disease that affects infants and young children. The company has also received approval from the U.S. Food and Drug Administration to initiate Phase I clinical trial of the HuCNS-SC cells as a potential treatment for Pelizaeus-Merzbacher Disease, a rare and fatal brain disorder that primarily affects young children. In addition, StemCells, through its wholly owned subsidiary, Stem Cell Sciences UK Ltd, is also pursuing applications of its cell-based technologies to develop research and drug screening tools, such as cell-based assays, and media and reagent tools. StemCells has exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents. The company was founded in 1988 and is based in Palo Alto, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.07
Volume	317418
Volume Avg	638876
52 Week High	9.80
52 Week Low	0.70
PE	N/A
PE (group average)	39
EPS Year	-1.70
EPS change Q/Q	-75%
EPS change Q/Q Yr ago	-40%
EPS change Q/Q next Q est	-75%
EPS change Y/Y	-35%
REV change Q/Q	133.33%
REV change Q/Q Yr ago	75%
EPS next Q est	-0.28
EPS next Y est	-1.25
Divident Annual	0.00
Dividend Yield	0%